Eli Lilly & Co. has agreed to buy ImClone Systems Inc. in an agreement and plan of merger (link is to sample merger agreements, as the Eli Lilly – ImClone merger agreement hasn’t been made public yet) for more than $6 billion. The merger would broaden Eli Lilly’s pipeline of cancer treatments and represents a blow to Bristol-Myers Squibb, which had marketed ImClone’s cancer drug Erbitux under a Development, Promotion and Marketing Agreement.
The deal prices ImClone at $70 per share in cash, more than 50% higher than its price in July before Bristol-Myers made its first bid. Both boards have approved and recommended that ImClone stockholders tender their shares. ImClone’s chairman, Carl Icahn, who owns about 14% of ImClone stock, has agreed to vote in favor of the Lilly deal. Icahn had taken over the position back in 2006, at which time the stock was trading in the mid-$30/share range.
The agreement and plan of merger has not yet been made publicly available, but if you need to find other merger agreements or marketing agreements drafted by top law firms, you can find them at www.RealDealDocs.com.
You must be logged in to post a comment.